MMR vaccine
The MMR vaccine is a vaccine against measles, mumps, and rubella (German measles).
 Mumps measles rubella vaccine | |
| Combination of | |
|---|---|
| Measles vaccine | Vaccine |
| Mumps vaccine | Vaccine |
| Rubella vaccine | Vaccine |
| Clinical data | |
| Trade names | M-M-R II, Priorix, Tresivac, Trimovax, others |
| Synonyms | MPR vaccine[1] |
| AHFS/Drugs.com | Multum Consumer Information |
| ATC code |
|
| Legal status | |
| Legal status |
|
  (what is this?) (verify) | |
The first dose is given to children around 9 to 15 months of age, with a second dose at 15 months to 6 years of age, with at least 4 weeks between the doses.[2][3] After two doses 97% of people are protected against measles, 88% against mumps, and at least 97% against rubella.[2]
The World Health Organisation sets a target of 95% needed to achieve and sustain measles elimination. In 2020/1 only 85.5% of five-year-olds in England were vaccinated.[4]
The vaccine is also recommended in those who do not have evidence of immunity,[2] and those with well controlled HIV/AIDS.[5][6] It is given by injection.[2]
References
- Grignolio, Andrea (2018). Vaccines: Are they Worth a Shot?. Springer. p. 2. ISBN 9783319681061.
- "MMR Vaccination What You Should Know Measles, Mumps, Rubella". CDC. 2 February 2018. Retrieved 10 September 2018.
- "Measles vaccines: WHO position paper – April 2017". Releve Epidemiologique Hebdomadaire. 92 (17): 205–27. 28 April 2017. PMID 28459148.
- "A Fresh Shot". Policy Exchange. Retrieved 2023-10-20.
- Kinney, Rebecca (2 May 2017). "Core Concepts - Immunizations in Adults - Basic HIV Primary Care - National HIV CurriculumImmunizations in Adults". www.hiv.uw.edu.
- Watson, JC; Hadler, SC; Dykewicz, CA; Reef, S; Phillips, L (22 May 1998). "Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 47 (RR-8): 1–57. PMID 9639369.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.